BACKGROUND: Increased uptake of hepatitis C virus (HCV) treatment among people who inject drugs (PWID) will be critical to achieve HCV elimination goals. There are limited data on HCV treatment uptake among PWID recruited from community-based settings in the HCV direct-acting antiviral (DAA) era. METHODS: We analysed data from PWID with HCV newly recruited into the Baltimore, Maryland-based AIDS Linked to the IntraVenous Experience (ALIVE) cohort between 2015 and 2018. We characterized the HCV care continuum and evaluated factors associated with HCV treatment uptake. RESULTS: Of the 418 PWID with HCV, the median age was 49 years and most (88%) reported recent injection drug use (IDU). Overall, 23% had ever been evaluated by a provider for HCV treatment, 17% ever initiated DAA treatment and 13% were cured of HCV infection. Treatment uptake approximately doubled between 2015 and 2018 (13% to 26%, P = .01). In multivariable analyses, HIV infection (adjusted Odds Ratio [aOR] 2.5 [95% Confidence Interval (CI) 1.3, 4.8]), current employment (aOR 4.1 [CI 1.2, 14.4]), having a primary care provider (aOR 4.3 [CI 1.2, 14.9) and longer duration of IDU (aOR 1.3 [CI 1.1, 1.6]) were positively associated with HCV treatment. PWID with a lower annual income (≤$5000) were less likely to have initiated HCV treatment (aOR 0.5 [CI 0.3, 0.98]). CONCLUSIONS: Although HCV treatment uptake among PWID in this community-based setting in the DAA era remains suboptimal, it is encouraging that treatment uptake has increased in recent years. Innovative strategies are needed to reach all PWID infected with HCV.
BACKGROUND: Increased uptake of hepatitis C virus (HCV) treatment among people who inject drugs (PWID) will be critical to achieve HCV elimination goals. There are limited data on HCV treatment uptake among PWID recruited from community-based settings in the HCV direct-acting antiviral (DAA) era. METHODS: We analysed data from PWID with HCV newly recruited into the Baltimore, Maryland-based AIDS Linked to the IntraVenous Experience (ALIVE) cohort between 2015 and 2018. We characterized the HCV care continuum and evaluated factors associated with HCV treatment uptake. RESULTS: Of the 418 PWID with HCV, the median age was 49 years and most (88%) reported recent injection drug use (IDU). Overall, 23% had ever been evaluated by a provider for HCV treatment, 17% ever initiated DAA treatment and 13% were cured of HCV infection. Treatment uptake approximately doubled between 2015 and 2018 (13% to 26%, P = .01). In multivariable analyses, HIV infection (adjusted Odds Ratio [aOR] 2.5 [95% Confidence Interval (CI) 1.3, 4.8]), current employment (aOR 4.1 [CI 1.2, 14.4]), having a primary care provider (aOR 4.3 [CI 1.2, 14.9) and longer duration of IDU (aOR 1.3 [CI 1.1, 1.6]) were positively associated with HCV treatment. PWID with a lower annual income (≤$5000) were less likely to have initiated HCV treatment (aOR 0.5 [CI 0.3, 0.98]). CONCLUSIONS: Although HCV treatment uptake among PWID in this community-based setting in the DAA era remains suboptimal, it is encouraging that treatment uptake has increased in recent years. Innovative strategies are needed to reach all PWID infected with HCV.
Authors: Sahar Bajis; Jason Grebely; Behzad Hajarizadeh; Tanya Applegate; Alison D Marshall; Mary Ellen Harrod; Jude Byrne; Nicky Bath; Phillip Read; Michael Edwards; Carla Gorton; Jeremy Hayllar; Victoria Cock; Steven Peterson; Claire Thomson; Martin Weltman; Meryem Jefferies; William Wood; Paul Haber; Nadine Ezard; Marianne Martinello; Lisa Maher; Gregory J Dore Journal: J Viral Hepat Date: 2019-12-06 Impact factor: 3.728
Authors: Shruti H Mehta; Becky L Genberg; Jacquie Astemborski; Ravi Kavasery; Gregory D Kirk; David Vlahov; Steffanie A Strathdee; David L Thomas Journal: J Community Health Date: 2008-06
Authors: Tianhua He; Kan Li; Mark S Roberts; Anne C Spaulding; Turgay Ayer; John J Grefenstette; Jagpreet Chhatwal Journal: Ann Intern Med Date: 2015-11-24 Impact factor: 25.391
Authors: Marija Zeremski; Jon E Zibbell; Anthony D Martinez; Steven Kritz; Bryce D Smith; Andrew H Talal Journal: World J Gastroenterol Date: 2013-11-28 Impact factor: 5.742
Authors: Oluwaseun Falade-Nwulia; Catalina Suarez-Cuervo; David R Nelson; Michael W Fried; Jodi B Segal; Mark S Sulkowski Journal: Ann Intern Med Date: 2017-03-21 Impact factor: 25.391
Authors: Jack Stone; Hannah Fraser; Aaron G Lim; Josephine G Walker; Zoe Ward; Louis MacGregor; Adam Trickey; Sam Abbott; Steffanie A Strathdee; Daniela Abramovitz; Lisa Maher; Jenny Iversen; Julie Bruneau; Geng Zang; Richard S Garfein; Yung-Fen Yen; Tasnim Azim; Shruti H Mehta; Michael-John Milloy; Margaret E Hellard; Rachel Sacks-Davis; Paul M Dietze; Campbell Aitken; Malvina Aladashvili; Tengiz Tsertsvadze; Viktor Mravčík; Michel Alary; Elise Roy; Pavlo Smyrnov; Yana Sazonova; April M Young; Jennifer R Havens; Vivian D Hope; Monica Desai; Ellen Heinsbroek; Sharon J Hutchinson; Norah E Palmateer; Andrew McAuley; Lucy Platt; Natasha K Martin; Frederick L Altice; Matthew Hickman; Peter Vickerman Journal: Lancet Infect Dis Date: 2018-10-29 Impact factor: 71.421
Authors: Marisa Felsher; Karin E Tobin; Mark Sulkowski; Carl Latkin; Oluwaseun Falade-Nwulia Journal: Drug Alcohol Depend Date: 2021-10-29 Impact factor: 4.492
Authors: Donna M Evon; Christopher B Hurt; Delesha M Carpenter; Sarah K Rhea; Caitlin M Hennessy; William A Zule Journal: Rural Ment Health Date: 2022-02-03
Authors: Maria A Corcorran; Judith I Tsui; John D Scott; Julia C Dombrowski; Sara N Glick Journal: Drug Alcohol Depend Date: 2021-01-11 Impact factor: 4.492